One overlooked American biotech just made your immune system 1,000 times more effective...

...Here's how it could make your portfolio 1,000 times healthier.

Dear Reader,

Deaths from earthquakes, wars, hurricanes, tsunamis, terrorism, and genocide grab all the headlines...

But disease is perennially the world's #1 killer — by hundreds of times over.

That's why it rarely makes headlines. Death from disease is simply too commonplace to be considered newsworthy. In the U.S. alone, the yearly body count is frightening to the point of near-disbelief... 

That's a total of 360,000 Americans killed every year from just 9 major diseases — more than 7 times the U.S. combat death count from the Vietnam War.

Imagine what the body count must be worldwide...

If the U.S. loses 360,000 people a year amidst the world's most advanced, highest-tech health care system... the rest of the globe must lose tens of millions of people to these diseases.

Now, what if I told you that one miniscule, all-but-ignored American bio-pharma firm owns the breakthrough that could soon render all these millions of deaths a thing of the past?

What if I told you that this company is already seeing success on human subjects using this technology that turns the genes of viruses and cancerous cells against themselves?

And what if I said that right now, you have a brief window of opportunity to scoop up shares of this destined-to-change-the-world company for less than $1.50 a piece?

That's the kind of once-in-your-life profit play that could conceivably turn every dollar you invest into $100 at least — and maybe $1000 or more...

Don't believe me?

I'll prove it to you right now...

How You Could've Banked More Than 2,000% Gains on "Breakthrough" Drugs that Save No More than 7,000 Americans per Year

Human Genome Sciences (HGS) was another micro-biotech firm that perfected a one-of-a-kind drug mechanism which cured a deadly disease: Lupus.

Not to downplay the impact of this painful autoimmune condition, but the truth is that Lupus is not very common — it affects only .53% of Americans — and it is highly survivable.

In fact, an average of less than 1,500 people died in the United States from Lupus each year before HGS's miraculous drug hit the market...

Nevertheless, when the news of their breakthrough's success in treating the disease came out, the company's stock shot up 276% in three days — and in less than 6 months, it was up over 1060%:

 

Cancer, as I'm sure you're aware, is thousands of times more prevalent than Lupus. Most of us have had the unfortunate experience of having or knowing someone who has had some form of cancer...

Now look at the 1,049% gains that micro-pharma Dendreon (DNDN) paid shareholders in the few short months following news of their "breakthrough" — a drug which cut the death rate from prostate cancer by a mere 20% (around 5,500 per year):

 

See how dramatic the gains of these under-the-radar biotechs can be?

Even for breakthroughs in the treatment of low-mortality diseases — or for advancements that merely chip away at the death tolls of major diseases — they can routinely pay a fast 10 times your money...

But can you imagine what would happen to your bottom line if you owned shares of a company with the superior drug technology that gave hope to hundreds of millions of virus and cancer sufferers?

The increase in their share prices would easily make the more than 2,000% gains you could have made on these micro-biotechs HGS and DNDN look like pennies at the bottom of a bucket...

Seriously: Think about what an ignored micro-pharma with the key to defeating almost every major killer disease on Earth (cancers, malarias, influenzas, HIV, and others) could pay you...

It would be no stretch at all to count on 100x returns on your investment.

And as I'll prove to you shortly, 1,000 times your money would not be out of the realm of possibility.

But only if you stocked up on shares while they were dirt-cheap and ignored. Wait too long on an opportunity like this, and everyone else will be counting your money...

So by now, surely you're dying to know: What's this technology that's going to revolutionize how we treat the world's deadliest diseases?

Well, let me start by showing you how effective it is against just ONE killer disease that terrorized the world not long ago...

How This Breakthrough Biotechnology Could've Saved Over 50 Million People in One Year

In 1918, a killer "Spanish Flu" pandemic terrorized the planet, infecting 1/3 of the world's population in one of the worst disease outbreaks in modern history...

And every year, one of the 13 strains of the flu threatens to break its restraints and evolve into a form as deadly as the 1918 strain.

But that's about to be a thing of the past.

If the results of the initial live trials hold true, then we can say that there now exists a technology which already has proven to be 100% effective against the strain that started this deadly plague.

In 1918, that would have meant over 50 million spared lives.

How could one drug have prevented all these deaths?

By combining two little-known and under-utilized technologies perfected by the revolutionary micro-biotech firm that I'll reveal to you shortly:

1. A type of vaccine known as a "Genetic Vaccine," and

2. A delivery system that makes that particular vaccine 1000 times more effective in initiating an immune response.

You see, viruses normally rely on molecular "lock picks" to get access into our own cells and then replicate. Our body's protection requires the production of antibodies, which either bolster our cellular "locks" to prevent the virus from entering into our cells or mark these viruses for destruction by our white blood cells.

This is also how traditional vaccines have worked for the past 80 years — they use dead virus strains to trick our immune system into developing antibodies so that they're prepared for an infection in the case one happens.

But while our bodies and vaccines are pretty amazing at defending our bodies from invaders, cancer cells and viruses are equally adept at eluding these bulwarks:

• Cancer cells, being simply mutated versions of our normal cells, are able to replicate beyond control because the body still recognizes them as its own, even though they now have different genes.

• Viruses replicate so fast and so often that they are able to change their "keys" at an unnerving speed, quickly rendering any immunity to that virus ineffective.

The virus' ability to, in effect, change their molecular lock picks has enabled them to always be one step ahead of the vaccine industry — which is why we have to get a different flu vaccine each year.

This highlights perhaps the biggest problem with our current vaccine technology: It can never be 100% effective.

But that's not the only problem with our current vaccine production methods:

• Traditional vaccines rely on pumping chicken eggs with viruses and waiting until they die to harvest and purify them, which means that our vaccine supplies must rely on the instability of the egg market.

• This process can take up to 6 months, which often provides vaccines too late for a seasonal epidemic like the flu.

• Relying on a live vaccine opens up the body to a multitude of side effects, not to mention the cost of extra protection measures during development needed for worker and public safety.

This may have flown during the 20^th century, but with new and more virulent diseases emerging at an exponential rate...

And cancer still relying on painful radiation and chemotherapy treatments that are never 100% effective...

Then we can all agree that a vaccine to take care of all the major viral and infectious diseases is long overdue.

Which is where the breakthrough company I'm about to reveal comes in.

While they've kept themselves under the radar, our featured micro-biotech firm is also not new to the vaccine scene; they've been developing this particular technology for the past 14 years...

In just a moment, I'm going to tell you all about how you could take advantage of this company's futuristic advancements to make those 100x-1000x gains I was telling you about earlier.

But first, let me tell you a little more about the technology that is also on its way to...

Bringing Investors 10,000% Returns by Destroying the Cancer Epidemic

Remember how I was telling you what keeps viruses coming back year after year is their ability to keep eluding our defenses by changing the picks to our bodies' cells?

Well, you can now consider that little viral trick a thing of the past.

That's because our firm's unique genetic vaccines utilize the virus' own DNA, which is genetically altered and then injected into cells to produce antibodies that are not fooled by the virus' change in picks.

And this is just the beginning:

• Because DNA is easily replicated in laboratory settings, the vaccine does not need to rely on chicken eggs to incubate the virus...
• Which not only means they have a more reliable source for the vaccine, but the turn-around time for its production is now a mere 2-3 weeks!
• Moreover, this type of vaccine — because it doesn't rely on a live virus — is able to be shipped and stored in a variety of conditions...
• Including those areas in developing countries that have difficulty storing traditional vaccines due to lack of refrigeration.

Add to this the ridiculously cheap cost of manufacturing genetic vaccines, and you have some great news for an industry already worth over $22.5 billion.

But it's also good news for those investors who've already started to ride this company's technological potential. The flu vaccine market alone pulls in over $4 billion.

Below, I'll tell you all about how investors are already cashing in on this incredible medical breakthrough — and how you can get in on the action, as well.

But before I do that, let me tell you about the second part of the technology that is making this small biotech firm a key player in the vaccine industry...

The Man-made Miracle of "Cell-Shock" Technology

"Cell-shock" technology is a delivery method that uses a small jolt of electricity to open the pores of the cells.

Normally, DNA molecules are too large to enter in the cell by themselves; it's a natural cellular defense to keep unwanted objects from entering.

But with the cell doors artificially stimulated, more of the genetic material in the vaccine is able to make it to a cell's replication center, increasing the number of antibodies the cell is able to produce.

This cell-shock technology is able to increase the uptake of DNA without the side effects normally associated with traditional vaccine types.

In other words, cell-shock technology is unmatched in its ability to safely, effectively, and economically deliver a genetically tailored vaccine to disease-ridden cells.

After 25 years and over $100 million in research, this overlooked micro-cap company has the dominant patent estate on this technology.

And if you move fast on their less-than-$1.50 shares, you could be setting yourself up for the biggest payday of your life.

I'm not talking about banking a quick ten bagger on some minor advancement in treating some insignificant disease...

I'm talking about the potential to rake in 100 to 1000 times your money or more on prevention and curative technology that'll change the world of medicine forever.

But you must hurry if you expect to cash in. Research universities and biotech companies across the world are already using this company's cell-shock method to deliver genetic vaccines with astounding success...

One European company using this technology has already completed Phase I vaccine trials for Hepatitis C, the leading cause of chronic liver disease in the United States.

That's just one of three other research partners using this company's patented cell-shock technology. And it doesn't end there, either...

This company has received over $25.1 million from both the government and various philanthropists and charities to develop a range of vaccines for everything from biodefense to diseases still running rampant in third world countries — like malaria.

With technology this revolutionary and partners this big, it won't take much to push this company to the forefront of the vaccine revolution.

Just below, I'll show you why it's crucial that investors get in on this action as soon as possible.

How to Make Record-breaking Profits From A Record-breaking Biotech

With a market cap of a under $120 million, our "Company X" is a David in a sea of Goliaths.

Just take a look at the market caps for this company, and those of three Big Pharma companies:

It's not even .01% the size of the smallest Big Pharma firm...

That's more than 1,000 times your money right there.

Think about it: Neither Novartis nor Roche has the patent on this revolutionary "cell-shock" technology — they couldn't cure and prevent cancer, HIV, influenza, or malaria even if they wanted to!

Plus, even for a mega-firm like Pfizer to produce even 100% gains, it has to effectively pull in over $153 billion — a practically impossible feat, even for a company with the research capabilities they have...

...But when you combine a market cap as small as our "Company X" with a miraculous medical technology on its way to curing the world's deadliest diseases, then even 10,000% gains would seem like a piece of cake.

Their ability to bring you ridiculous gains lies in their uniqueness: They're one of those rare companies who have been able to harness both a genetic vaccine and a delivery method that yields promising results for multiple diseases.

Instead of focusing on one specific virus or cell that causes one specific kind of cancer or disease, our little biotech start-up has been focusing on isolating the genes of several of mankind's biggest killers.

So while they're using the same vaccine technology for each disease, this technology is able to effectively fight any virus or cancer cell that has the potential to harm the human body.

The ability to produce multiple medical applications is key in an industry that is expected to push global revenues of...

More Than $45 Billion in Annual Sales by 2015

And that's just the vaccine industry!

Already, other biotech companies are trying to ramp up production of vaccines that can treat and cure multiple conditions — cancer and the flu, for example...

But they'll fall utterly short of what this micro-biotech I'm telling you about today can accomplish.

Whereas most companies' vaccines are preventative measures, the kinds of genetic vaccines this firm specializes in are able to treat the disease even after infection has occurred.

You see, genetic vaccines fall under a broader category of therapeutic vaccines: vaccines which are able to produce antibodies that fight the intruding organism long after the virus or cancer has taken hold.

Take the human papilloma virus (HPV) for instance...

This virus causes genital warts — and it's the major cause of cervical cancer among woman. HPV has managed to infect over 20 million women in the U.S. alone.

It has also pushed cervical cancer to be the second deadliest cancer among women in the world.

While there is already a preventative vaccine out there for HPV, it does not help the women who are already infected — or the millions of others who remain undiagnosed.

Fortunately, our little biotech company has already started human testing on a genetic vaccine that can give hope to the millions of American women who are already suffering from HPV and cervical cancer.

But that's just the start for this little firm.

Preliminary animal tests of this company's "cell shock" system have already shown 100% protection against the H1N1 version currently sweeping the globe!

This is why you must get in on this stock RIGHT NOW. Even overcoming an obstacle as small as moving this vaccine into animal trials is enough to push this stock's gains well over 200%.

That's right: This stock has already tripled in recent months on early word of what it can do.

The Vaccine That Will Turn Your $5,000 Investment Into An Easy $500K Return

This company is on the verge of surpassing several major obstacles in the next couple of months:

• 1 vaccine is already in the middle of Phase II human trials;

• 6 vaccines are nearing the end of Phase I human trials;

• 1 vaccine is awaiting confirmation to move into Phase I human trials;

• 4 others are finishing up their animal trials and on the verge of applying to continue to humans.

Every phase that one of these 12 vaccines passes to is another good bump to this company's stock.

The further along the vaccine is, the more you can expect the stock to rise...

... Completing any one of the human trials could easily see your gains reach triple-digits — or even more.

Especially when you consider that share prices for this stock are ridiculously low right now. I'm talking well under $1.50.

And while that is extremely good news to investors like you and me, it is becoming ultra-urgent that you get in on this stock as soon as possible. News of this company's success in any of its trial phases could be easy triple-digit gains that you miss out on. 

I'm going to tell you all about this biotech bonanza in our newest report... 

This report details the one company we've found that's on the edge of bringing the drug industry's "holy grail" to market — a single system for combating (and all but curing) the world's biggest killers...

I'll also tell you how this report can be yours absolutely FREE.

But before I go any further, let me tell you a bit more about myself and my colleague who discovered this little gem...

Introducing The Wealth Advisory... And How You Can Get 6 Months of its Money-Making Research for FREE

My name is Brian Hicks, and I'm the publisher of the financial newsletter The Wealth Advisory. 

For the past nine years, The Wealth Advisory has endeavored to provide some of the best contrarian investment advice available anywhere.

We focus on making investors like you money in all types of markets, whether we're in the bliss of a bull run or in the pangs of this recent recession.

That's where my friend and colleague Steve Christ comes in.

You see, even during 2008 and 2009's depression-inducing bear market, Steve managed to seal a whopping 55 double-digit gainers for investors just like you.

That number makes Wall Street's "wins" look like child's play in comparison.

And that's why I'm writing you today.

Steve recently pushed his newest report across my desk detailing the small biotech firm which is on the leading edge of universal vaccine development. He calls it Big Pharma's Holy Grail: The Vaccine of the Century.

I call it one of the most historic medical breakthroughs and unprecedented investment opportunities I have ever seen.

After sending him out west to interview the President and CEO, Steve reported to me that he is even more confident that this company is really set to take off.

When Steve tells me he found another company ready to give investors a run for their money, I tend to believe him.

Steve is a meticulous man who does his research, which is why I funded this particular trip to the other side of the country. I wouldn't have trusted anyone else to go.

I've even sent him as far as China, Australia, and even Mexico — all so he could bring our readers the most up-to-date and profitable investment information around.

I don't mind spending money for Steve's research. He's worth every penny.

After all, he recently picked and closed Orexigen therapeutics, which gained 378% in less than five months! 

If you don't believe me, just check out the graph:

This is no freak occurrence, either. Take a quick look at some of his other winners:

• Adobe Systems Inc. (ADBE: NASDAQ) closed with a 32.28% gain in 11 weeks.

• Converted Organics Inc. (COIN: NASDAQ) closed with a 42.11% gain in two weeks.

• FXP UltraShort FTSE/Xinhua China 25 Proshare (FXP: AMEX) closed with a 27.23% gain in four weeks.

• Morgan Stanley China - SHORT POSITION (CAF: NYSE), a 32.51% gain in four weeks.

• PowerShares DB Commodity Idx Trking Fund (DBC: AMEX), a 14.26% gain in eight weeks.

• PowerShares DB Energy (DBE: AMEX), a 15% gain in nine weeks.

• VMware Inc. (VMW: NASDAQ), a 44.44% gain in eight weeks.

• Chesapeake Energy (CHK: NYSE), a 15.4% gain in 6 weeks.

• UltraShort QQQ ProShares (QID: NASDAQ), a 11% gain 4 weeks.

• PowerShares DB Oil (DBO: AMEX), a 49% gain in 5 months.

• UltraShort FTSE/Xinhua China25 Proshare (FXP: AMEX), a 16.45% gain in 2 days.

• UltraShort MSCI Emerging Markets Proshare (EEV: AMEX), a 19.6% gain in 2 days.

• W.R. Grace & Co. (GRA: NYSE), a 72.12% gain in under 3 weeks!

That's a cumulative gain of 776.7% versus losses of only 99.2 % — a net gain of 677.5%!

With our newest pick found in Big Pharma's Holy Grail: The Vaccine of the Century, we only expect to add to this total.

So, here's how to find out about this explosive biotech gem in...

Your FREE Copy of Big Pharma's Holy Grail: The Vaccine of the Century

When you sign up for your no-hassle, 6-month, risk-free subscription to the award-winning Wealth Advisory, you'll be able to jump straight into the profitable world of the biotech industry with our freshest report — absolutely free.

This is your easy immediate access to an industry player that's going to revolutionize the word "vaccine" as we know it... and can make you your own cash revolution in the process.

But that's not the only thing I want to give you.

I'm going to send you FOUR MORE of The Wealth Advisory's insider reports at no additional cost!

So in addition to Big Pharma's Holy Grail: The Vaccine of the Century, you'll receive:

• The Brewing Biotech Bull Market: This report documents another biotech company leading the way in stem cell research and already being targeted for a Big Pharma buy-out.

• Commercial Real Estate: How to Profit When the Other Shoe Drops: Learn about how some basement bargain real estate stocks are on the verge of pulling in double-baggers in the coming months.

• The Secrets of the Plunge Protection Team: There's a small group of federally sanctioned insiders working to prop up our very own U.S. stock market. The "free" market isn't as free as you think it is. This report covers the "Plunge Protection Team" and their presidential directive...

• The 376-Year Old Investment Technique That Never Fails in a Down Market: Steve reveals the trade secrets of one of the most infamous investors in U.S. history — a secret that's been underutilized for over three centuries.

With your subscription to The Wealth Advisory , you'll soon be part of an elite service dedicated to making money even during one of the worst recessions in history.

(And remember, for the next 6 months, you can test drive The Wealth Advisory — including everything I described above — with zero risk.)

But don't take my word for it. Just listen to what some of my subscribers have to say:

If you want to brag like this to your friends and family, then let me tell you...

 

How to Get the Wealth Advisory... for only $79 a year!!!!

No, you're not seeing things. For only $79 a year, you can reap the benefits of the massive amounts of time and travel that Steve puts into his research.

That's $60 less than a Wall Street Journal subscription... and more than $200 cheaper than a subscription to the New York Times!

And I guarantee that they won't make you nearly as much money as we will.

So let's recap...

When you sign up for your risk-free, 6-month trial subscription to The Wealth Advisory, you'll immediately receive:

1. Your free copy of Big Pharma's Holy Grail: The Vaccine of the Century;

2. Four more FREE reports detailing everything from the real estate market to centuries old investment secrets;

3. Instant Buy/Hold/Sell Alerts via e-mail so you can get the most strategic and efficient trading done to maximize your profits;

4. Admission to our entire winning portfolio — access to over 71 different stocks and over 71 chances to increase the income of your own portfolio;

5. Access to our archives — your chance to look into all the tricks of the trade that have made The Wealth Advisory one of the most successful investment services around;

6. Our 110% Iron-Clad Guarantee — We're so confident that we'll make your pockets burst at the seams with money that, if for any reason you become unsatisfied with your subscription within the first 6 months, we'll completely refund every last penny without any question. And you can even keep your five special reports as our gift to you.

Now's Your Time to Become 1,000x Healthier and 1,000x Richer

This is one of those rare opportunities to make a difference, both in the lives of others and in your own portfolio.

There are millions of lives to be saved — and millions of dollars to be made — by harnessing the quantum leaps in technology that this "Holy Grail" company has already demonstrated as possible.

But if you want to take part in this rare investment opportunity, it's urgent that you act upon this offer soon...

Our little universal vaccine maker is already making headlines again by expanding their patents for their particular technology — and this could easily be the news that rockets their share prices from bargain penny stock to triple-digit bank buster.

Which means that you could see those easy five-digit gains evaporate before your eyes.

So let's show death the door. To earn your treasures from death's demise, just click on the button below.

I promise you won't be disappointed.

To Your Wealth and Health,

Brian Hicks
Publisher, The Wealth Advisory

P.S. Things just got a little more urgent than we thought. A recent law passed extending drug patents an extra 5 years has just opened the door for major Big Pharma buyouts of small biotech firms like our "Company X." Buying up smaller firms saves biotechs lots of money and research time, since the smaller companies do all the work. The thing with Big Pharma buyouts is that they can easily produce high double-digit and even triple-digit gains in short order. When Bristol-Myers Squibb bought out Medarex, Medarex's stock rose 90.4% in just a few days, while news of this made rival firm Medivation's stock rise over 101%. These are quick gains you do not want to miss out on — it's as simple as clicking here.